CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Total revenue	$ 86,977	$ 101,713	$ 193,007	$ 197,290
COST OF REVENUE	58,971	52,747	118,632	101,209
Total gross profit	28,006	48,966	74,375	96,081
Operating expenses:
General and administrative	34,613	29,577	70,957	61,719
Research and development	2,105	2,587	4,165	3,796
Sales and marketing	10,195	12,324	23,453	23,540
Total operating expenses	46,913	44,488	98,575	89,055
(Loss) income from operations	(18,907)	4,478	(24,200)	7,026
Interest expense, net	1,548	1,304	2,367	3,130
Other (income) expense, net	(7,405)	(10)	(7,628)	5,159
Loss on extinguishment of debt	1,400	1,018	1,400	1,018
Loss on termination of cash flow hedge	3,506	0	3,506	0
(Loss) income before taxes	(17,956)	2,166	(23,845)	(2,281)
Income tax (benefit) expense	(11,132)	175	(10,043)	(1,848)
Net (loss) income	$ (6,824)	$ 1,991	$ (13,802)	$ (433)
NET (LOSS) INCOME PER SHARE
Basic (in dollars per share)	$ (0.06)	$ 0.02	$ (0.13)	$ (0.00)
Diluted (in dollars per share)	$ (0.06)	$ 0.02	$ (0.13)	$ (0.00)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic (in shares)	107,887	98,297	106,209	96,734
Diluted (in shares)	107,887	102,336	106,209	96,734
Clinical Services
Total revenue	$ 73,884	$ 88,982	$ 166,866	$ 175,192
Total gross profit	25,127	42,602	69,186	86,161
Pharma Services
Total revenue	13,093	12,731	26,141	22,098
Total gross profit	$ 2,879	$ 6,364	$ 5,189	$ 9,920